Last reviewed · How we verify
Pegylated filgrastim
Pegylated filgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in chemotherapy patients.
Pegylated filgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in chemotherapy patients. Used for Chemotherapy-induced neutropenia in patients with non-myeloid malignancies, Reduction of infection risk in cancer patients receiving myelosuppressive chemotherapy.
At a glance
| Generic name | Pegylated filgrastim |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) analog |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim is a recombinant human G-CSF that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their proliferation, differentiation, and activation. Pegylation extends the drug's half-life by reducing renal clearance, allowing for less frequent dosing compared to standard filgrastim while maintaining sustained neutrophil production during chemotherapy-induced neutropenia.
Approved indications
- Chemotherapy-induced neutropenia in patients with non-myeloid malignancies
- Reduction of infection risk in cancer patients receiving myelosuppressive chemotherapy
Common side effects
- Bone pain
- Headache
- Fatigue
- Nausea
- Injection site reactions
- Splenomegaly
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated filgrastim CI brief — competitive landscape report
- Pegylated filgrastim updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI